RBFC
VRTX icon

Roman Butler Fullerton & Co’s Vertex Pharmaceuticals VRTX Stock Holding History

Roman Butler Fullerton & Co’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$784K Buy
1,632
+26
+2% +$11.5K 0.19% 126
2026
Q1 		$713K Buy
1,606
+2
+0.1% +$933 0.2% 124
2025
Q4 		$750K Buy
1,604
+10
+0.6% +$4.31K 0.2% 123
2025
Q3 		$665K Sell
1,594
-1,983
-55% -$829K 0.18% 130
2025
Q2 		$1.68M Buy
3,577
+489
+16% +$225K 0.5% 47
2025
Q1 		$1.55M Buy
3,088
+1,521
+97% +$709K 0.6% 41
2024
Q4 		$695K Sell
1,567
-83
-5% -$38.5K 0.22% 106
2024
Q3 		$799K Sell
1,650
-1
-0.1% -$480 0.24% 98
2024
Q2 		$811K Buy
1,651
+5
+0.3% +$2.17K 0.26% 88
2024
Q1 		$658K Buy
1,646
+301
+22% +$127K 0.25% 97
2023
Q4 		$578K Sell
1,345
-4,142
-75% -$1.53M 0.23% 110
2023
Q3 		$2.04M Sell
5,487
-410
-7% -$143K 0.96% 26
2023
Q2 		$2.11M Buy
5,897
+456
+8% +$154K 0.97% 25
2023
Q1 		$1.81M Sell
5,441
-492
-8% -$148K 0.9% 23
2022
Q4 		$1.85M Sell
5,933
-72
-1% -$21.9K 0.96% 22
2022
Q3 		$1.77M Sell
6,005
-602
-9% -$173K 1.13% 18
2022
Q2 		$1.94M Buy
6,607
+5,277
+397% +$1.41M 1.07% 20
2022
Q1 		$347K Buy
+1,330
New +$316K 0.16% 144
2021
Q3 		– Sell
-1,185
Closed -$239K – 197
2021
Q2 		$239K Buy
1,185
+223
+23% +$46.6K 0.12% 172
2021
Q1 		$213K Buy
+962
New +$211K 0.11% 191
2020
Q4 		– Sell
-4,008
Closed -$1.09M – 180
2020
Q3 		$1.09M Sell
4,008
-337
-8% -$93K 0.71% 45
2020
Q2 		$1.26M Buy
4,345
+38
+0.9% +$10.3K 0.9% 30
2020
Q1 		$1.02M Buy
4,307
+2,181
+103% +$500K 0.9% 31
2019
Q4 		$465K Buy
+2,126
New +$430K 0.31% 101
2019
Q1 		– Sell
-2,405
Closed -$447K – 185
2018
Q4 		$447K Buy
+2,405
New +$417K 0.38% 98

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Roman Butler Fullerton & Co's VRTX Position: Q2 2026 in Review

Roman Butler Fullerton & Co increased its Vertex Pharmaceuticals (VRTX) stake by 1.6% in Q2 2026, buying an estimated $11.5K and bringing the position to 1,632 shares worth $784K. The position accounts for 0.19% of the portfolio, ranked #126.

Roman Butler Fullerton & Co first reported a position in VRTX in Q4 2018 and has held it in 25 quarters since. The position peaked at $2.11M in Q2 2023. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Roman Butler Fullerton & Co held 1,632 shares of Vertex Pharmaceuticals worth $784K as of Q2 2026.
  • Roman Butler Fullerton & Co bought 26 Vertex Pharmaceuticals shares in Q2 2026, an estimated $11.5K.
  • Vertex Pharmaceuticals made up 0.19% of Roman Butler Fullerton & Co's portfolio in Q2 2026, its #126 holding.
  • Roman Butler Fullerton & Co first reported a position in Vertex Pharmaceuticals in Q4 2018 and has held it in 25 quarters since.
  • Roman Butler Fullerton & Co's Vertex Pharmaceuticals position peaked at $2.11M in Q2 2023.
  • 1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Roman Butler Fullerton & Co's 13F filing for Q2 2026, filed 6 Aug 2026.